Post by Hot Christian Stocks on Dec 15, 2013 20:15:44 GMT -5
rockingpennystocks.com/
PLPL
Company Website
www.plandaibiotech.com/
I am excited to be able to post a new interview with or V.P. Callum Baylis Duffield
click here for interview
thestockradio.com/plpl-plandai-biotechnology-inc-v-p-global-director-of-marketing-sales-callum-baylis-duffield/
Thursday news recap
Plandai Biotechnology's CEO Discusses Direction of Medical Marijuana Subsidiary
NEW YORK, NY--(Marketwired - Dec 12, 2013) - Plandaí Biotechnology's (OTCQB: PLPL) subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company's CEO, Roger Duffield, announced it will address neural disorders with its marijuana research. In that announcement Duffield said, "We believe that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, and post-concussion syndrome."
Plandaí, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments.
Duffield said, "Our research affirms that damage to the CB1 and CB2 brain receptors contributes to several neuron diseases. Cannabis is rich in neuron-beneficial phytocannabinoids including Δ9-THC; however, Δ9-THC taken in an oral preparation converts in the liver to 11-hydroxy metabolite. This new chemical demonstrates high levels of psycho-activity and is significantly less effective in scavenging free radicals. Essentially, you get the psychotropic aspects of the drug with none of the medicinal benefits."
Unlike other biotechs engaged in marijuana research, Plandaí's extraction and hydrodynamic sheering process combined with its Pheroid™ technology, should allow it to produce an extract that captures and enhances the phytocannabinoids while ideally leaving behind the phychotropic effects.
READ FULL PRESS RELEASE HERE
www.marketwired.com/press-release/plandai-biotechnologys-ceo-discusses-direction-of-medical-marijuana-subsidiary-otcqb-plpl-1861803.htm
ABOUT THE COMPANY
Plandaí Biotechnology, Inc. intends to transform the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. Their headquarters are in Seattle, Washington, USA. Although they also have a global presence with offices in London, England and Nelspruit in the province of Mpumalanga, South Africa. This enables them to react more efficiently to any worldwide market changes as well as to any customer requirements.
Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 8500 acres, in the province of Mpumalanga, South Africa.
Products and benefits
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. They believe through their studies that this is between 60-80%, far exceeding anything currently available today.
Their extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)
Senteeko Estate
Plandaí Biotechnology, Inc., through its wholly owned subsidiaries, farms over 7500 acres of luscious land in the Mpumalanga province of South Africa.
It farms a whole fruit basket of produce which it uses in its creation of highly bioavailable extracts, ranging from citrus to avocado pears to most notably over 2000 acres of tea.
The tea plant, Camellia Sinensis, is an evergreen shrub or tree and can grow to heights of 30ft though for cultivation is pruned to heights of 2-5ft.
Farming in South Africa is like no other country in the world and because of this we needed to make sure that we stacked the deck in our favour and employed only the best as ever y step of the product creation pathway is critical. With that in mind, our farming team has over 100 years of experience in managing farms in Southern Africa.
Community and Social Responsibility
Understanding what happened in the past is integral to ensure that the mistakes are not repeated in the present and future.
From the 1960’s to early 2004, the tea industry in South Africa enjoyed relative stability and protection from market prices. That is, until the SADC tariffs were dropped and international tea prices plummeted forcing the South African tea industry to virtually collapse overnight affecting more than 50,000 employees.
Plandaí Biotechnology, through its wholly owned subsidiary’s notarial leases, is undertaking to revive not only the tea estates and other farms but also to empower the local communities who will benefit from employment and education opportunities, thanks to scholarship programs that are being set up to identify and nurture the brightest talent.
Furthermore, the farms, under the management of Plandaí Biotechnology wholly owned subsidiary, Dunn Roman Holdings-Africa (Pty) Ltd will comply with the Global Gap farming regulations.
Research and Development
THE TREATMENT OF INFLAMMATORY CONDITIONS WITH CITRUS BIOFLAVONOIDS
The corticosteroid blood level is enhanced
Treatment of rheumatic fever is improved by inclusion of citrus bioflavonoids in the therapeutic regimen.
The frequency and severity of rheumatic epistaxis (nose-bled) is diminished by citrus bioflavonoids
Maintenance of Capillary Integrity
Athletic Injuries and Citrus Bioflavonoid Therapy
The Common Cold
News
Plandai Biotechnology's CEO Discusses Direction of Medical Marijuana Subsidiary
NEW YORK, NY--(Marketwired - Dec 12, 2013) - Plandaí Biotechnology's
( OTCQB : PLPL ) subsidiary, Cannabis Biosciences, Inc., will be developing
and testing a botanical extract derived from cannabis, and the company's
CEO, Roger Duffield, announced it will address neural...
12/12/2013 8:45:00 AM
Plandai Biotechnology, Inc. Announces Intellectual Property Filings
SEATTLE, WA--(Marketwired - Dec 11, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutraceutical, and pharmaceutical, today announced
that over the past several months the c...
12/11/2013 9:00:00 AM
Plandai Biotechnology, Inc. to Focus Marijuana Research on Neuron Disorders Including Alzheimer's, Parkinson's, and Multiple Sclerosis
SEATTLE, WA--(Marketwired - Dec 9, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutriceutical, and pharmaceutical, today released
a statement from company Chairman and Ch...
12/9/2013 9:00:00 AM
Plandai's Medical Marijuana Research Could Benefit From FDA Approval of Clinical Trials
NEW YORK, NY--(Marketwired - Nov 26, 2013) - Plandaí Biotechnology
( OTCQB : PLPL ) timed its move into medical marijuana research perfectly.
This month the U.S. Food and Drug Administration (FDA) approved clinical
trials of the cannabis-based drug, Epidolex, and its eff...
11/26/2013 8:30:00 AM
Plandai to Provide New Formula in Diet Industry Profit Quest
BALTIMORE, MD--(Marketwired - Nov 20, 2013) - Goldman Small Cap Research,
a stock market research firm focused on the small cap and microcap sectors,
notes that while high profile weight loss companies are failing to deliver
revenue and profits the door is wide open for a...
11/20/2013 9:05:00 AM
New Report Shows Plandai Biotechnology's Diabetes Research More Important Than Ever
NEW YORK, NY--(Marketwired - Nov 19, 2013) - Late last week the
International Diabetes Federation (IDF) released a report filled with some
staggering statistics in the fight against diabetes. Plandaí Biotechnology, Inc.
( OTCQB : PLPL ) feels it is producing products tha...
11/19/2013 8:30:00 AM
Plandai Biotechnology's Move Into Medical Marijuana Research Gets Validation With New Study
NEW YORK, NY--(Marketwired - Nov 14, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ) and its subsidiary, Cannabis Biosciences, Inc., received
a strong validation for their move into medical marijuana research from a
recently published study.
Plandaí formed its mariju...
11/14/2013 8:30:00 AM
Plandai Enters Medical Marijuana Market
BALTIMORE, MD--(Marketwired - Nov 1, 2013) - Goldman Small Cap Research,
a stock market research firm focused on the small cap and microcap sectors,
notes that in a move that could add meaningful value to the overall company,
Plandaí Biotechnology, Inc. ( OTCQB : PLPL ) ...
11/1/2013 9:05:00 AM
Plandai Biotechnology Enters Medical Marijuana Arena With Industry-Changing Technology
NEW YORK, NY--(Marketwired - Oct 31, 2013) - Plandaí Biotechnolgy, Inc.
( OTCQB : PLPL ) announced this week that it has entered the medical
marijuana industry with its new wholly-owned subsidiary,
Cannabis Biosciences, Inc., for the purpose of developing and testing a n...
10/31/2013 8:30:00 AM
Plandai Biotechnology, Inc. to Enter Medical Marijuana Field With Phyto Cannabinoid Extract
SEATTLE, WA--(Marketwired - Oct 30, 2013) - Plandaí Biotechnology, Inc.
(OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutriceutical, and pharmaceutical, today announced
that it has formed a new wholly-owned s...
10/30/2013 9:00:00 AM
Plandai Preparing for Strong 2014
BALTIMORE, MD--(Marketwired - Oct 24, 2013) - Goldman Small Cap Research,
a stock market research firm focused on the small cap and microcap sectors,
notes that a series of development milestones and clinical trials scheduled to
conclude or commence this quarter and early...
10/24/2013 1:20:17 PM
Plandai Biotechnology, Inc. Featured in Farmer's Weekly, South Africa's Oldest Agricultural Magazine
SEATTLE, WA--(Marketwired - Oct 16, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutriceutical, and pharmaceutical, today announced
that it has been featured in the Octobe...
10/16/2013 11:59:45 AM
Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market
NEW YORK, NY--(Marketwired - Oct 3, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ) has several clinical trials already underway, and a host of
others scheduled to commence in the company months as the company
feverishly prepares products for market in its transitio...
10/3/2013 9:30:00 AM
Plandai Biotechnology, Inc. Enters Fourth Quarter Stronger Than Ever With Pheroid(TM) Technology
NEW YORK, NY--(Marketwired - Oct 2, 2013) - Plandaí Biotechnology Inc.
( OTCQB : PLPL ) already has a technology in place that is allowing it to boast
of higher bioavailability with its Phytofare™ products than other nutraceutical
producers in the industry; however, the ...
10/2/2013 8:45:00 AM
Plandai Biotechnology, Inc. Announces New Extract in Its Ongoing Fight Against Malaria
SEATTLE, WA--(Marketwired - Oct 1, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutriceutical, and pharmaceutical, today announced
that it is developing a new Phytofare™ ...
10/1/2013 9:00:00 AM
Plandai Scores Lucrative License Deal
BALTIMORE, MD--(Marketwired - Sep 26, 2013) - Goldman Small Cap Research,
a stock market research firm focused on the small cap and microcap sectors,
notes that less than a month removed from acquiring rights to a cutting edge
nano and micro particle entrapment technology,...
9/26/2013 9:00:00 AM
Plandai Biotechnology, Inc. Executes Letter of Intent to Sell All Estimated 2014 Phytofare Limonoid Production
SEATTLE, WA--(Marketwired - Sep 25, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutraceutical, and pharmaceutical, today announced
that it has executed a letter of inten...
9/25/2013 9:00:00 AM
Plandai Biotechnology, Inc. Announces Agreement With Oasix, Inc. to Distribute Phytofare Pheroid Topical Products
SEATTLE, WA--(Marketwired - Sep 24, 2013) - Plandaí Biotechnology, Inc.
( OTCQB : PLPL ), a producer of highly bioavailable plant extracts for industries
including health, wellness, nutriceutical, and pharmaceutical, today announced
that it has sold an exclusive license ...
9/24/2013 9:00:00 AM
follow us on: twitter.com/RockingPenny
Disclaimer:Rockingpennystocks.com. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Rockingpennystocks employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at www.Rockingpennystocks.com/disclaimer.php Release of Liability: Through use of this website/newsletter viewing or using you agree to hold Rockingpennystocks its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Rockingpennystocks affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Rockingpennystocks.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Rockingpennystocks makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Rockingpennystocks.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Rockingpennystocks.com has been compensated $1500 cash for the distribution of this email and other marketing services from Microcap Innovations a non controlling third party. We may or may not hold a position and reserve the right to buy or sell shares at any time, which may positively or negatively affect the price per share. This not a solicitation to buy or sell any securities. Rockingpennystocks nor any of its affiliates are registered investment advisers or broker dealers.
rockingpennystocks.com/